Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib + Famitinib for biochemical recurrence during PARPi maintenance in ovarian cancer (Phase 2)
ChiCTR2600123414Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib and famitinib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: CA-125 response rate and Progression-free survival (PFS). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
fluzoparibfamitinib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ChiCTR2600123414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123414.